Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing

AIMS/INTRODUCTION: A single‐dose, shield‐activated pen‐injector for each of the three approved dose variants (0.25, 0.5 and 1 mg) of once‐weekly subcutaneous semaglutide has been developed to improve usability. This analysis presents findings from the summative usability testing process for the sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Klonoff, David C, Bassock, Stephanie, Dwyer, Andrea, Engels, Ella, Qvist, Marianne, Sparre, Thomas, Snitker, Soren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169358/
https://www.ncbi.nlm.nih.gov/pubmed/33034163
http://dx.doi.org/10.1111/jdi.13429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169358/
https://www.ncbi.nlm.nih.gov/pubmed/33034163
http://dx.doi.org/10.1111/jdi.13429

Ejemplares similares